Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS G12C-mutant colorectal cancer, drawn from the whole corpus: 19 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses last months, not years; acquired RAS and MAPK alterations drive resistance.
Nothing recorded yet.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
G12D, the commonest colorectal KRAS allele, has no approved drug.
Nothing recorded yet.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
First-line use of the combinations awaits CodeBreaK 301 and KRYSTAL-10.
Anti-EGFR skin and magnesium toxicity limits the combinations for some patients.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
KRAS G12C colorectal cancer with panitumumab (CodeBreaK 300)
KRAS G12C colorectal cancer with panitumumab
A milestone in how this cancer is treated.
KRAS G12C colorectal cancer with cetuximab (accelerated)
KRAS G12C colorectal cancer with cetuximab